OXALIPLATIN "EBEWE" 100mg/20ml Infusion/Powder for

What is OXALIPLATIN "EBEWE" 100mg/20ml

OXALIPLATIN "EBEWE" is a chemotherapy medicine that contains the active substance Oxaliplatin. It is supplied as a powder for infusion and must be reconstituted before administration.

• Therapeutic Class: Antineoplastic agent (platinum-based)
• Indications: Primarily used in the treatment of colorectal cancer, especially in combination with other anticancer agents like 5-fluorouracil and leucovorin.
• Form: Powder for concentrate for solution for infusion (100mg in 20ml vial)
• Administration: Intravenous infusion after dilution
• Color/Appearance: White to off-white lyophilized powder

Oxaliplatin is typically used in the adjuvant setting (post-surgery) and in metastatic colorectal cancer. It plays a critical role in halting cancer cell growth and spreading.

How to use OXALIPLATIN "EBEWE" 100mg/20ml

The use of Oxaliplatin should be under the supervision of an experienced oncologist. Proper administration and dosing are crucial to minimize side effects and maximize therapeutic effects.

• Reconstitution: The powder must be dissolved in a compatible solution (commonly 5% glucose solution) before being further diluted for infusion.
• Infusion Duration: Typically administered as a 2–6 hour intravenous infusion.
• Frequency: Usually given once every 2 weeks in combination with other chemotherapy drugs.
• Preparation: Reconstituted and diluted in a chemotherapy hood using protective equipment.
• Monitoring: Close monitoring is required during infusion, especially for signs of hypersensitivity or peripheral neuropathy.
• IV Access: Administer through a central or peripheral vein with appropriate precautions to avoid extravasation.

Always follow your oncologist's exact instructions regarding dosage and infusion schedule. Never attempt to self-administer or alter your schedule without medical supervision.

Mode of Action OXALIPLATIN "EBEWE" 100mg/20ml

Oxaliplatin works through a well-understood cytotoxic mechanism typical of platinum compounds. Its anticancer activity is due to its ability to interfere with DNA replication and transcription.

• DNA Cross-Linking: Forms covalent platinum-DNA adducts which create intra- and inter-strand crosslinks, inhibiting DNA replication.
• Apoptosis Induction: These crosslinks activate DNA damage responses, leading to apoptosis (programmed cell death) in cancer cells.
• Cell Cycle Arrest: Interrupts the S-phase and G2-phase of the cell cycle, effectively stopping cell proliferation.
• Synergy: Often used with 5-fluorouracil, enhancing overall cytotoxic effects on rapidly dividing tumor cells.

Oxaliplatin differs from older platinum agents (like cisplatin) by having a diaminocyclohexane (DACH) carrier ligand, which improves cellular uptake and reduces resistance in some cancer types.

OXALIPLATIN "EBEWE" 100mg/20ml Interactions OXALIPLATIN "EBEWE" 100mg/20ml

Drug interactions can affect the safety and efficacy of Oxaliplatin. It is important to inform your doctor about all medications you are taking.

• Aminoglycosides: Increased risk of nephrotoxicity and ototoxicity when used concurrently.
• Live Vaccines: Avoid live attenuated vaccines (e.g., yellow fever) due to immunosuppressive effects of chemotherapy.
• Nephrotoxic Agents: Caution with other nephrotoxic drugs such as amphotericin B, vancomycin, or NSAIDs.
• Anticoagulants: Increased bleeding risk, especially if mucositis occurs. Monitor INR if on warfarin.
• Cisplatin: Avoid simultaneous use due to potential additive toxicity and unclear benefits.

Routine laboratory monitoring and careful medical history are essential before starting Oxaliplatin to avoid harmful interactions.

Dosage of OXALIPLATIN "EBEWE" 100mg/20ml

Dosage is based on body surface area (BSA) and individualized according to treatment protocol and patient tolerance.

• Standard Dosage: 85 mg/m² every 2 weeks when used in combination therapy (e.g., FOLFOX regimen).
• Adjustment: Dose may be reduced in patients with renal impairment or severe side effects.
• Cycle Duration: Repeated every 14 days in most regimens.
• Maximum Cumulative Dose: Neurotoxicity is dose-limiting; treatment may be paused if persistent neuropathy develops.
• Premedication: Antiemetics such as ondansetron are recommended before administration to reduce nausea.

Dosing must be determined by an oncologist based on lab results, patient health status, and treatment goals. Never alter your dose without professional consultation.

Possible side effects of OXALIPLATIN "EBEWE" 100mg/20ml

Like all chemotherapy agents, Oxaliplatin can cause side effects ranging from mild to severe. Monitoring and supportive care can help manage these effects.

• Common Side Effects:
  • Peripheral neuropathy (cold-induced or chronic)
  • Nausea, vomiting, and diarrhea
  • Fatigue and weakness
  • Stomatitis (mouth sores)
• Hematologic Side Effects:
  • Neutropenia
  • Thrombocytopenia
  • Anemia
• Serious Adverse Effects:
  • Hypersensitivity reactions (rash, dyspnea, anaphylaxis)
  • Severe neurotoxicity leading to functional impairment
  • Liver enzyme elevation and hepatotoxicity

Report any unusual symptoms to your oncologist immediately. Supportive medications are often prescribed to reduce the severity of side effects.

OXALIPLATIN "EBEWE" 100mg/20ml Contraindications OXALIPLATIN "EBEWE" 100mg/20ml

Oxaliplatin is not suitable for all patients. Several absolute and relative contraindications must be considered.

• Hypersensitivity: Known allergy to Oxaliplatin or other platinum-containing compounds.
• Pregnancy and Breastfeeding: Contraindicated due to teratogenicity and unknown effects on lactation.
• Severe Renal Impairment: Risk of increased toxicity; use is generally avoided or dose adjusted.
• Pre-existing Neuropathy: May worsen peripheral neuropathy; careful risk-benefit assessment required.
• Myelosuppression: Avoid in patients with bone marrow suppression until recovery of blood counts.

Before starting therapy, patients should undergo full clinical evaluation and laboratory testing to rule out contraindications.

Storage of OXALIPLATIN "EBEWE" 100mg/20ml

Proper storage conditions are critical to maintaining the efficacy and safety of this chemotherapy agent.

• Unreconstituted Vial: Store at 2°C–8°C (refrigerated). Do not freeze. Protect from light.
• Reconstituted Solution: Should be used immediately. If needed, it may be stored for a limited time (as per manufacturer's instructions) under specific conditions.
• Diluted Solution: Should be administered within a few hours of preparation to avoid degradation.
• Disposal: Follow hospital cytotoxic waste procedures. Do not dispose in general waste or sewage.

Always keep the medicine out of reach of children and ensure safe handling by trained personnel using protective equipment.